VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

Similar documents
MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING

Section 5. Study Procedures

Section 5. Study Procedures

Section 8. Clinical Considerations

Overview of Enrollment/Initiate Period 1 Visit Procedures

Section 9. Laboratory Considerations

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

PDF of Trial CTRI Website URL -

Section 5. Study Procedures

MTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

1/9/ :00:00AM 1/9/ :39:34AM 6/9/2017 9:08:54AM A/c Status. Test Name Results Units Bio. Ref. Interval 70.00

2018 Preventive Schedule

GSK , 2.0, 18, 2014, DAIDS

Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -

9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-035.

Action Item for 2019 Review of Tool. Maintain (add include oral cavity) Maintain. Archive. Archive. 12 creatinine)

MTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018

Youth Entering Detention Incarcerated youth are more likely to be from low socioeconomic status families who have inadequate access to health care. De

HPTN 035. Laboratory Overview

FY 2018 PERFORMANCE PLAN. Public Health/ CHSB

Med Chem 535P ~ Diagnostic Medicinal Chemistry. General Comments

2018 Preventive Schedule

HIV Basics: Clinical Tests and Guidelines

Specimen Management PHRU LAB

WOMEN'S INTERAGENCY HIV STUDY

MTN-038 Laboratory Training. May Beamer, Michele Austin MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated

ASPEN MOUNTAIN MEDICAL CENTER. Lab Health Fair

BASIC METABOLIC PANEL

SFAF CLINICAL PROTOCOLS

ENROLLMENT CONFIRMATION

Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313

VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

* * Interpretation

Inspector's Accreditation Unit Activity Menu

Online catalog

Practical Approaches of Integrating HCV into HIV Care David Hachey, Pharm.D., BCPS, AAHIVP Professor Idaho State University

2019 Preventive Schedule Effective 1/1/2019

COMPANY OR UNIVERSITY

Refugee Health Funding Models: A Review of PA Models and A Vision for the Future

Annual Notice to Providers (2014)

Clinician Blood Panel Results

Hamilton Regional Laboratory Medicine Program

Hamilton Regional Laboratory Medicine Program

Prior to site activation the following events were lined up

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Percentage of family planning clinics, according to clinic characteristics, by service focus, Title X funding status and clinic type, 2010 and 2015

Synopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

Follow-up Visit Procedures MTN-009

Rapid Laboratories In House Tests

SMALL ANIMAL SOFT TISSUE CASE-BASED EXAMINATION

Specimen Collection Requirements

Presentation to the Worcester Board of Health Matilde Castiel MD June 9, 2016

2016 Preventive Health Care Guidelines. Free preventive care to help you be your healthiest.

Clinical Considerations. Review

Specimen Collection Requirements

SydPath Reference Intervals for Clinical Trials (Contract Pathology Unit) Unauthorised Copy

2017 Preventive Health Care Guidelines

Complete Blood Count (CBC) Assist.Prof. Filiz BAKAR ATEŞ

PEDIATRIC - INFANCY PREVENTIVE HEALTH CARE GUIDELINES

MEDICAL HISTORY. 23-Jan-2018 to 23-Jan VCA Miller-Robertson Animal Hospital 8807 Melrose Ave, Los Angeles, CA (310)

Section 6. Participant Follow-up

Prenatal-Postpartum Care Guidelines, Paramount

2017 Preventive Schedule

Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1

Clinician Blood Panel Results

STI Indicators by STI

2018 Preventive Schedule Effective 1/1/2018

H.6.G.2 Non-MAC Studies

Subject ID: I N D # # U A * Consent Date: Day Month Year

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

HYPERCALCEMIC GOLDEN RETRIEVER

Patient Information Specimen Information Client Information. Specimen: EN255254W. Requisition:

East Carolina University Student Health Service

Prevents future health problems. You receive these services without having any specific symptoms.

PrEP in the Real World: Clinical Case Studies

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

2018 Preventive Schedule Effective 1/1/2018

5/6/ :35:00AM 5/6/ :57:28AM 5/6/2017 3:49:09PM A/c Status. Test Name Results Units Bio. Ref. Interval

Pre Exposure Prophylaxis Health Program

LabDriver Audit Trail Example

HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS

Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations

Ages 19 to 49: Every 1 to 2 years Ages 50 and older: Once a year Once a year. High-risk. High-risk. High-risk

M.D.IPA, M.D.IPA Preferred, Optimum Choice and Optimum Choice Preferred STAT Laboratory List Revised Jan. 5, 2017

2014 Preventive Health Care Guidelines. Grandfathered plans. We want to help you be your

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.

SMALL ANIMAL SOFT TISSUE CASE- BASED EXAMINATION

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Patient Information Specimen Information Client Information. Specimen: EN255254W. Requisition: TSENG, JUSTINA J DOB: 10/26/1955 AGE: 59

QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing

Cleveland Prevention Update. Zach Reau HIV Prevention Program Manager Ohio Department of Health

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

2017 Preventive Schedule

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Transcription:

VOICE Screening Part 1 Visit Operational Walkthrough Johannesburg, South Africa November 2008

Protocol Requirements Administrative, Behavioral, and Regulatory Procedures Informed consent for screening Demographic information Behavioral eligibility information, using the Screening Part 1 Eligibility form Locator information

Protocol Requirements Administrative, Behavioral, and Regulatory Procedures HIV pre-test counseling HIV/STI risk reduction counseling Offer HIV counseling and testing for partners Provision of condoms Reimbursement Schedule next visit (if applicable)

Operational Considerations Administrative, Behavioral, and Regulatory Procedures Participant identification and checking for co-enrollment in other studies are not listed as required procedures in the protocol, but should be performed at each visit

Operational Considerations Administrative, Behavioral, and Regulatory Procedures Obtain written informed consent before performing any screening procedures Determine participant age as part of the screening informed consent process Date of informed consent for screening begins the 56-day screening and enrollment period

Protocol Requirements Clinical Procedures Medical eligibility information Using the Screening Part 1 Eligibility form May require clinician review of TB status Weight Urine collection (15-60 ml) Blood collection (approximate volumes) 15 ml in red top tubes (plain or serum separator) 6 ml in lavender top tube (EDTA)

Protocol Requirements Clinical Procedures Pelvic exams may be performed at Screening Part 1 if local standards of care require an exam to guide treatment of STI/RTI symptoms

Protocol Requirements Clinical Procedures Disclosure of available test results Treatment for UTI/STI/RTI if clinically indicated Offer of STI testing and treatment for partners if indicated Ascertainment of current contraceptive method (if any) and contraceptive counseling Provision of contraception if indicated per site SOP

Operational Considerations Clinical Procedures Time required to evaluate current genital symptoms STI/RTI treatment regimens Use single-dose observed regimens No test of cure required But treatment must be completed and any symptoms resolved before enrollment

Protocol Requirements Laboratory Procedures Urine pregnancy test Dipstick urinalysis for protein, glucose, nitrites, and leukocyte esterase Urine SDA for gonorrhea and chlamydia

Protocol Requirements Laboratory Procedures HIV serology Syphilis serology Complete blood count with differential and platelets Serum chemistries: AST, ALT, creatinine, phosphate Hepatitis B surface antigen test Hepatitis B surface antibody test

CBC With Differential Required elements per protocol Hemoglobin Hematocrit MCV Platelets White blood cells Neutrophils absolute count AND percentage Lymphocytes absolute count Monocytes absolute count Eosinophils absolute count Basophils absolute count

Operational Considerations Laboratory Procedures Volume of testing for eligibility criteria Coordination of clinic and lab Days and hours of operation Transporting and tracking specimens Tracking result reports Monitoring temperature and maintaining QC/QA for tests performed in clinic

Operational Considerations Laboratory Procedures Calculating creatinine clearance (140-age in years) x (weight in kg) x (0.85) 72 x serum creatinine in mg/dl

Operational Considerations Laboratory Procedures Tracking dipstick urinalysis results across screening and enrollment visits If 2+ or greater for protein or glucose INELIGIBLE If 1+ for protein or glucose repeat testing at Screening Part 2

Operational Considerations Scheduling next visit 56-day screening and enrollment period Number of Screening Part 2 visits that can be scheduled on any one day Time required to receive lab test results Participant s menstrual period Current UTI/STI/RTI symptoms / time to resolution following treatment Any other current exclusionary conditions / time to resolution Continue current screening attempt?

Sequence of Procedures Check for co-enrollment before proceeding to screening informed consent process Obtain informed consent before performing any screening procedures Assign PTID after informed consent obtained Provide HIV pre-test counseling before collecting blood for HIV testing Order procedures for maximum screening efficiency perform procedures with highest expected screen-out rate first and minimum waiting time during visit Stop when participant found to be ineligible

What are your questions?

Questions for Site Input What study information materials would you provide to potentially eligible participants at the end of the Screening Part 1 visit? Would you spend time explaining/discussing these materials at the Screening Part 1 visit, or wait until the Screening Part 2 visit?